What is ALS Phase 2 Study KNS-760704 CL201?

Category: Others

false

See also: ALS Phase 2 Study KNS-760704 CL211

NCT00647296 is a 2 part, randomized, double-blind, safety and tolerability study evaluating the drug KNS-760704 in patients with amyotrophic lateral sclerosis (ALS). The drug KNS-760704 is now known as dexpramipexole. Other study ID includes: KNS-760704-CL201.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 0
Moderate 0
Mild 1
None 2

Commonly reported side effects and conditions associated with ALS Phase 2 Study KNS-760704 CL201

Side effect Patients
Dry mouth 1

Why patients stopped taking ALS Phase 2 Study KNS-760704 CL201

Multiple reasons could be selected

Reason Patients
Course of treatment ended 2
See all 2 patients who've stopped using ALS Phase 2 Study KNS-760704 CL201

Duration

Stopped using ALS Phase 2 Study KNS-760704 CL201

Duration Patients
6 months - 1 year 1
2 - 5 years 1
Adherence
Adherence Evaluations
Always 3
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 1
A little hard to take 1
Not at all hard to take 1
Cost per month
Cost per month Evaluations
$200+ 0
$100-199 0
$50-99 0
$25-49 0
< $25 3
Not specified 0
Last updated:

1 patient evaluation for ALS Phase 2 Study KNS-760704 CL201

Oct 24, 2009 (Started Jul 01, 2008)

  • Effectiveness
    Major (for Participate in clinical trial)
  • Effectiveness
    Can't tell (for amyotrophic lateral sclerosis)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    Somewhat hard to take
Dosage: Daily
Advice & Tips: This Clinical Trial is to evaluate the tolerabiltiy and effectiveness of an investigational drug. Initially a double blind placebo-controlled study, the research is now in an open-label phase where I know I am taking the active compound. The research results are not yet known . Personally I can't tell if it has slowed the progression of symptoms since I have never had ALS before! The burden of this treatment involves traveling over 100 miles every month or two to the research site, for EKG, blood work, urinalysis, two spinal taps, physical exams, medication logs,and other requirements of the research protocol.
Cost: < $25 monthly

  • 4 helpful marks
Last updated:
Showing 1 of 1 patient evaluation for ALS Phase 2 Study KNS-760704 CL201